Literature DB >> 35046107

Loss of Ribosomal Protein Paralog Rpl22-like1 Blocks Lymphoid Development without Affecting Protein Synthesis.

Shawn P Fahl1, Robert Sertori1, Yong Zhang1, Alejandra V Contreras1, Bryan Harris1, Minshi Wang1, Jacqueline Perrigoue1, Siddharth Balachandran1, Brian K Kennedy2, David L Wiest3.   

Abstract

Ribosomal proteins are thought to primarily facilitate biogenesis of the ribosome and its ability to synthesize protein. However, in this study, we show that Rpl22-like1 (Rpl22l1) regulates hematopoiesis without affecting ribosome biogenesis or bulk protein synthesis. Conditional loss of murine Rpl22l1 using stage or lineage-restricted Cre drivers impairs development of several hematopoietic lineages. Specifically, Tie2-Cre-mediated ablation of Rpl22l1 in hemogenic endothelium impairs the emergence of embryonic hematopoietic stem cells. Ablation of Rpl22l1 in late fetal liver progenitors impairs the development of B lineage progenitors at the pre-B stage and development of T cells at the CD44-CD25+ double-negative stage. In vivo labeling with O-propargyl-puromycin revealed that protein synthesis at the stages of arrest was not altered, indicating that the ribosome biogenesis and function were not generally compromised. The developmental arrest was associated with p53 activation, suggesting that the arrest may be p53-dependent. Indeed, development of both B and T lymphocytes was rescued by p53 deficiency. p53 induction was not accompanied by DNA damage as indicated by phospho-γH2AX induction or endoplasmic reticulum stress, as measured by phosphorylation of EIF2α, thereby excluding the known likely p53 inducers as causal. Finally, the developmental arrest of T cells was not rescued by elimination of the Rpl22l1 paralog, Rpl22, as we had previously found for the emergence of hematopoietic stem cells. This indicates that Rpl22 and Rpl22l1 play distinct and essential roles in supporting B and T cell development.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35046107      PMCID: PMC8827804          DOI: 10.4049/jimmunol.2100668

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo.

Authors:  Y Y Kisanuki; R E Hammer; J Miyazaki ; S C Williams; J A Richardson; M Yanagisawa
Journal:  Dev Biol       Date:  2001-02-15       Impact factor: 3.582

Review 2.  Specialized ribosomes: a new frontier in gene regulation and organismal biology.

Authors:  Shifeng Xue; Maria Barna
Journal:  Nat Rev Mol Cell Biol       Date:  2012-05-23       Impact factor: 94.444

3.  RPL39L is an example of a recently evolved ribosomal protein paralog that shows highly specific tissue expression patterns and is upregulated in ESCs and HCC tumors.

Authors:  Queenie Wing-Lei Wong; Jia Li; Sheng Rong Ng; Seng Gee Lim; Henry Yang; Leah A Vardy
Journal:  RNA Biol       Date:  2013-12-20       Impact factor: 4.652

4.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

5.  VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages.

Authors:  Pantelis Georgiades; Sarah Ogilvy; Hélène Duval; Diana R Licence; D Stephen Charnock-Jones; Stephen K Smith; Cristin G Print
Journal:  Genesis       Date:  2002-12       Impact factor: 2.487

Review 6.  Ribosomopathies: There's strength in numbers.

Authors:  Eric W Mills; Rachel Green
Journal:  Science       Date:  2017-11-03       Impact factor: 47.728

7.  Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs.

Authors:  Yong Zhang; Anne-Cécile E Duc; Shuyun Rao; Xiao-Li Sun; Alison N Bilbee; Michele Rhodes; Qin Li; Dietmar J Kappes; Jennifer Rhodes; David L Wiest
Journal:  Dev Cell       Date:  2013-02-25       Impact factor: 12.270

8.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

9.  Haematopoietic stem cells require a highly regulated protein synthesis rate.

Authors:  Robert A J Signer; Jeffrey A Magee; Adrian Salic; Sean J Morrison
Journal:  Nature       Date:  2014-03-09       Impact factor: 49.962

10.  Twenty years of ribosome assembly and ribosomopathies.

Authors:  Jonathan R Warner
Journal:  RNA       Date:  2015-04       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.